Detalhe da pesquisa
1.
Empagliflozin after Acute Myocardial Infarction.
N Engl J Med
; 390(16): 1455-1466, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587237
2.
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Circulation
; 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38743805
3.
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial.
Circulation
; 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38581389
4.
Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
Circulation
; 148(24): 1919-1928, 2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37850397
5.
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
N Engl J Med
; 384(21): 1981-1990, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33999548
6.
Outcomes of peripheral artery disease and polyvascular disease in patients with end-stage kidney disease.
J Vasc Surg
; 79(5): 1170-1178.e10, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38244643
7.
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Circulation
; 146(16): 1196-1206, 2022 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36030390
8.
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
Lancet
; 399(10333): 1383-1390, 2022 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35385695
9.
Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study.
Am Heart J
; 259: 30-41, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36642226
10.
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE.
Am Heart J
; 264: 31-39, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37290700
11.
Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial.
J Card Fail
; 29(8): 1113-1120, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37331690
12.
Morbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical Trials.
J Card Fail
; 29(12): 1603-1614, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37479054
13.
Timing of sedation and patient-reported pain outcomes during cardiac catheterization: Results from the UNTAP-intervention study.
Catheter Cardiovasc Interv
; 2023 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36640418
14.
Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study.
Vasc Med
; 28(2): 122-130, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37025023
15.
Importance of patient engagement in the conduct of pragmatic multicenter randomized controlled trials: The ADAPTABLE experience.
Clin Trials
; 20(1): 31-35, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35999816
16.
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.
Am Heart J
; 253: 86-98, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35595091
17.
Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial.
J Vasc Surg
; 75(2): 660-670.e3, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34597783
18.
World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial.
Vasc Med
; 27(1): 21-29, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34516308
19.
Impact of risk factor control on peripheral artery disease outcomes and health disparities.
Vasc Med
; 27(4): 323-332, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35387516
20.
Timing Is Everything - Evidence for When to Perform Complete Revascularization in STEMI.
N Engl J Med
; 389(15): 1427-1428, 2023 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37819959